Elucidation of molecular mechanism and prevention strategy for patient with schizophrenia based on a rare case

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K14973
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Natural medicines
• Research Institution: Tokyo Metropolitan Institute of Medical Science
• Principal Investigator: ARAI Makoto 公益財団法人東京都医学総合研究所, 精神行動医学研究分野, プロジェクトリーダー (80356253)
• Co-Investigator(Renkei-kenkyūsha): MIYASHITA Mitsuhiro 公益財団法人東京都医学総合研究所, 精神行動医学研究分野, 主席研究員 (60532132)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: 天然活性物質 / 統合失調症 / ヤマブシタケ / メタボローム / 終末糖化産物

Outline of Final Research Achievements

Hericium erinaceum (HE) is a unique mushroom for its cognitive function improving actions (Inanaga et al., 2014). Amyloban 3399 contains Amycenon, a standardized extract of HE, and is currently being tested for safety as a health food supplement. Inanaga reported that PANSS of 10 schizophrenic patients before and after the administration of Amyloban had dramatically improved without side effects. Based on this clinical observations, we challenged to clarify relationship phenomena and metabolites before and after taking Amyloban. We assessed alteration levels of metabolite in a male case who had been treatment-resistant and severe side effects for more than thirty years by using LC-MS/MS techniques in both his urine and plasma samples. We found that several metabolites were remarkably changed before and after administration of this supplements. In the future, we will need to study the effects of specific metabolites on symptoms using a larger number of patients with schizophrenia.

Free Research Field

生物学的精神医学、生化学、病態代謝学